Evidence map›Paper›PMID 25227585›Full record

ArticleJournal of neuroimmunology2014

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.

Cyd Castro-Rojas, Krystin Deason, Rehana Z Hussain, Liat Hayardeny, Petra C Cravens, Felix Yarovinsky, Todd N Eagar, Benjamine Arellano, Olaf Stüve

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cyd Castro-RojasDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Krystin DeasonDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Rehana Z HussainDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Liat HayardenyTeva Pharmaceuticals, Petah Tikva, Israel.
Petra C CravensDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Felix YarovinskyDepartment of Immunology, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Todd N EagarHistocompatibility and Transplant Immunology, Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Houston, TX, USA.
Benjamine ArellanoDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA.
Olaf StüveDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, TX, USA; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany. Electronic address: olaf.stuve@utsouthwestern.edu.

Funding

INTEGRATIVE IMMUNOLOGY TRAINING PROGRAMT32AI005284 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Nan Yan · 2003 to 2026
$7.4M
NIAID NIH HHS T32 AI005284
6 · The paper itself

Abstract

Immune surveillance of the CNS is critical for preventing infections; however, there is no accepted experimental model to assess the risk of infection when utilizing disease-modifying agents. We tested two approved agents for patients with multiple sclerosis (MS), glatiramer acetate and fingolimod, in an experimental model of CNS immune surveillance. C57BL/6 mice were infected with the ME49 strain of the neuroinvasive parasite Toxoplasma gondii (T. gondii) and then treated with GA and fingolimod. Neither treatment affected host survival; however, differences were observed in parasite load and in leukocyte numbers in the brains of infected animals. Here we demonstrate that this model could be a useful tool for analyzing immune surveillance.

Indexed as

AnimalsAntigens, CDCentral Nervous SystemDisease Models, AnimalFingolimod HydrochlorideGlatiramer AcetateImmunologic SurveillanceImmunosuppressive AgentsMiceMice, Inbred C57BLPeptidesPropylene GlycolsSphingosineToxoplasmosisAntigens, CDFingolimod HydrochlorideGlatiramer AcetateImmunosuppressive AgentsPeptidesPropylene GlycolsSphingosineEAEExperimental autoimmune encephalomyelitisImmune surveillanceToxoplasma gondii

Identifiers

PMID25227585
PMCPMC4296723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.